Detection of minimal residual disease (MRD) in acute lymphoblastic leukemia with flow cytometry is based on precise description of leukemia cell at diagnosis including aberrant expression of determinants. The important clinical significance of MRD is in time of obtaining the first remission of acute leukemia. The problems with MRD assay and interpretation of results in acute lymphoblastic B and T leukemia are discussed.